RecruitingNCT04249375
Integrating Pediatric Pharmacogenomic Testing Into the Canadian Health Care System
Sponsor
University of British Columbia
Enrollment
150 participants
Start Date
Feb 20, 2020
Study Type
OBSERVATIONAL
Conditions
Summary
This project addresses the problem of adverse drug reactions in the three most frequently prescribed therapeutic classes of drugs in children: antibiotics, analgesics, and mental health medications. We will conduct pilot testing of a pharmacogenomic testing panel and study how the tests and generated test results are utilized and understood by physicians, pharmacists, patients and their families.
Eligibility
Inclusion Criteria1
- Participants will be enrolled if they can benefit from pharmacogenomic testing. This means their physician is considering the use of a drug that is part of the panels (analgesics, antibiotics, and mental health medication) or they are already using one.
Exclusion Criteria1
- Patients who do not speak or understand English.
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04249375
Related Trials
Interprofessional Pharmacogenomics (IPGx) Registry and Repository
NCT067265901 location
Pharmacogenomics-Supported Psychotropic Prescribing Trial
NCT069295332 locations
National Active Surveillance Network and Pharmacogenomics of Adverse Drug Reactions in Children
NCT004141151 location
IPGx PILOT Whole Genome Sequencing Extension Cohort
NCT067660711 location